Further, PD-1 blockade did not show any increase in survival or any histopathological changes in glioma patients, thus suggesting a difference in the mutational landscape of hypermutated gliomas as compared to other types of immune-responsive hypermutated cancers [40]. The gene discussed is PDCD1; the disease is central nervous system cancer.